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ABSTRACT  
 
Background: 
Rheumatoid Arthritis (RA) is a chronic auto-immune musculoskeletal disorder of unknown 
aetiology that can result in physical disability, chronic pain and impaired quality of life. RA is 
associated with an increased prevalence of depression.  The presence of depression in RA is 
reported to be associated with pain, functional disability, high disease activity and mortality.  
   
This study aims to determine the prevalence of depressive symptoms in a cohort of Black 
South African patients attending a Rheumatology outpatient clinic at a public health center. It 
also aims to determine the association and correlation between the presence of depressive 
symptoms and the sociodemographic profile and RA clinical characteristics of the study 
population.  
 
Methodology: 
The study was conducted in a Rheumatology out patient clinic.  The study sample consisted of 
100 systematically selected participants of Black race. The participants completed the 
disability questionnaire (HAQ-DI), Visual Analogue Scales (VAS) for pain, fatigue and 
disease activity; and the depression and tension subscales of the Arthritis Impact Measurement 
Scale (AIMS). The MADRS was then administered to assess depressive symptoms. 
 
v 
 
Study participants were clinically assessed for disability, joint status and disease activity.  
Data was analyzed using the SAS version 9.1 statistical program. 
Results: 
 The majority of the sample was female (85%) and unmarried (66%). The prevalence of 
current depression was 13.2%, although a further 22.2% of the sample was already stable on 
antidepressant treatment. The mean RA disease duration was 12.5 ± 9.2 years.  
 
No significant associations were found between the presence of depression and the 
sociodemographic variables. MADRS scores were significantly associated and correlated with 
disability (p = 0.002, r = 0.30); fatigue (p = <0.001, r = 0.43); disease activity (p = 0.001,  
r = 0.32); AIMS-D (p < 0.001, r = 0.40) and AIMS-T (p < 0.001, r = 0.35). Upon adjusting for 
age and clinical status, significant associations remained with MADRS scores and all five 
above-mentioned RA variables although correlations weakened slightly.  
 
Conclusions:  
Co morbid depression is prevalent in South African Black patients with RA. In order to 
improve clinical outcomes in RA, depression must be actively sought and effectively 
managed.   
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CHAPTER ONE: INTRODUCTION 
 
Rheumatoid Arthritis (RA) is a chronic auto-immune musculoskeletal disorder of unknown 
aetiology. It affects approximately one percent of the population (range 0.3 to 2.1 percent) 
with women being three times more likely to be affected than men.
1 
The disorder is 
characterized by joint destruction and extra-articular manifestations; that can result in physical 
disability, chronic pain and impaired quality of life.  
 
Sprangers et al compared the results of eight studies looking at the quality of life in a wide 
range of chronic disorders, affecting various organ systems. The study found that 
musculoskeletal conditions like RA were associated with the most adverse sequelae and the 
poorest quality of life.
2
 
 
 
In view of its clinical manifestations, chronicity and impact on quality of life, RA is expected 
to be associated with an increased prevalence of depression. 
 
Indeed, various studies have reported that between 13-20% of patients with RA have co-
morbid depression, reflecting at least a two-fold increase in depression as compared to the 
general population.
3, 4, 5
 One of these studies noted that the effect size of depression in those 
study patients was not reduced when controlling for age, sex and socioeconomic status; 
suggesting that the depression was due to RA and not sociodemographic factors.
3  
 
 
2 
 
Depression in RA is also associated with other disease manifestations. The most  
robust findings being, in its association with pain, functional disability, disease activity and 
mortality.
3,
 
4
 
 
1.1 Rationale: 
 
There is a paucity of published data on the psychological aspects, including prevalence of 
depressive symptoms and its associations with other disease characteristics in South African 
RA patients.
6
  
 
Evidence was reported that South African patients of African (Black) descent experience more 
sociodemographic disadvantage and higher degrees of functional disability than non-African 
patients. The occurrence and burden of depressive symptoms is therefore expected to be high 
in this patient population.
7
   
 
1.2 Research Aims: 
 
1) To determine the prevalence of depressive symptoms in a cohort of Black African 
patients with RA, attending a public health centre in South Africa. 
2) To determine the association between the presence of these depressive symptoms with 
patient sociodemographic and other RA disease manifestations.  
 
 
3 
 
1.3 Hypothesis: 
 
There is a high prevalence of depressive symptoms in Black South African patients with RA, 
attending the Rheumatology outpatient clinic at the Charlotte Maxeke Johannesburg 
Academic Hospital. 
 
The presence of depressive symptoms is associated with increased pain, greater functional 
disability and increased disease activity.  
 
1.4 Study Approval: 
 
This study was approved by the Human Research Ethics Committee (HREC) of the University 
of the Witwatersrand [Appendix A]. Permission to conduct the study was also granted by the 
Chief Executive Officer (CEO) of the Charlotte Maxeke Johannesburg Academic Hospital.  
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CHAPTER TWO: LITERATURE REVIEW 
 
2.1 RA and Depression 
 
2.1.1 Prevalence  
 
Assessing prevalence rates of depression in RA, as with most chronic medical disorders, has 
been fraught with difficulties. These include variable patient populations, type of screening 
tool used (self-report questionnaire versus clinical interview) and overlap in RA disease and 
depression symptomatology (termed „criterion contamination‟). Despite this, and the varying 
prevalence rates detected, the literature generally supports a positive relationship between 
depression and RA.
3, 5, 6  
Very early prevalence studies like that of Rimon and Laakso , as cited 
by Creed et al  quote prevalence rates of between 22 and 80%, with more recent studies 
narrowing the rate to between 15- 21%.
8, 9, 10
  
 
 Pincus et al attempted to obtain a more accurate prevalence rate of depression in RA patients, 
by removing symptoms in the screening tools that may contribute to criterion contamination. 
Although the prevalence rates for depression detected were found to be lower (15%), RA 
patients were still found to be significantly more depressed than controls.
10
  
 
A 2002 meta analysis of the literature, found 12 studies which compared RA sufferers with 
healthy controls. The findings indicated that subjects with RA were more likely to be 
depressed, with a small to moderate effect size noted. Additionally, the authors concluded that 
5 
 
the excess of depression as compared to healthy controls was due to the presence of RA and 
not sociodemographic factors.
3
 
 
More recent studies  looking at the prevalence rates of depression in RA do not seem to differ 
much in their findings either with rates of 41.5% and 56.7% respectively, being reported.
11, 12
 
The study by Isik et al included an age- and sex-matched control group and not only found a 
higher prevalence rate of depression but also positively correlated depression with a longer 
RA disease duration.
11
 Mella et al compared RA patients with Osteoarthritis (OA) patients in a 
study looking at the prevalence rates of depression in a Brazilian population. In addition to 
finding a higher prevalence of depression in the RA patients, the authors also found that the 
RA patients with depression had a lower education level, higher disease activity and greater 
functional disability than non-depressed RA patients.
12
 
 
Despite the challenges faced in detecting and confirming prevalence rates of depression in the 
RA  patient population, studies consistently point  not only to a positive relationship between 
these two disorders; but  also to a negative impact on health outcomes when they coexist.  
 
2.1.2 Impact of Depression on RA 
 
Dickens and Creed in an editorial on the burden of depression in patients with RA reflected 
not only on the negative impact of the presence of depression on pain and functional 
disability, but also on the reaction of these patients to their illness. Negative illness beliefs, 
increased health-seeking behaviour, increased reports of physical symptoms and high service 
6 
 
utilization seem to be characteristic of this patient group. In addition and concerning for 
patient health outcomes, was the observation that these patients displayed reduced medication 
compliance and a lack of confidence in their treating doctors.
13
  
 
Regarding the role of psychosocial factors in RA, two factors emerge as important: stressful 
life events (particularly of an interpersonal nature) and the presence of depression. In a study 
comparing the impact of depression, on RA sufferers with a group of Osteoarthritis (OA) 
patients; the RA group was found to have greater reactivity to perceived stress and arthritis  
pain.
14
 
 
The ultimate consequence of the impact of depression in patients with RA seems to be poorer 
health outcomes and greater healthcare costs. 
 
2.1.3 Detecting Depression in RA 
 
Obtaining an accurate indication of the presence of co morbid depressive symptoms or a 
depressive disorder within the context of a medical disorder like RA can be challenging.  
This is, firstly, due to the difficulty of differentiating the neurovegetative symptoms of 
depression (fatigue, appetite and weight changes, and sleep difficulties) from the similar 
somatic manifestations of RA; termed „criterion contamination‟.15 Secondly, there does not 
appear to be an ideal measurement instrument or process to accurately determine the presence 
of depression within this cohort of patients. Even structured clinical interviews are thought to 
be susceptible to criterion contamination.
16 
7 
 
In an attempt to reduce or, at best, modify this phenomenon numerous studies have looked at 
different measurement scales that can be used to best assess the presence of depression within 
the RA and more generally, medical populations.
17, 18, 19. 20
 
 
At the core of this discussion is the use of self-report versus observer rating scales. In terms of 
rating scales developed for use within the general population, the Beck Depression Inventory 
(BDI) is reported to be the most widely used. The disadvantage of this scale, as with other 
self-report measurement scales, is its tendency to overestimate the severity of depressive 
symptomatology in patients who present with somatic complaints.
18
 The use of the BDI in RA 
subjects would for this reason probably be limited. 
 
The Hamilton Depression Rating Scale (HDRS) and Montgomery- Asberg Depression Rating 
Scale (MADRS) are probably two of the most well known observer rating scales for 
depression.  With regard to their use in medically ill populations, the MADRS is considered a 
better alternative as it includes fewer somatic items, thereby reducing the possibility of falsely 
elevated depression score as a result of criterion contamination.
19, 21, 22
 
 
 Demyttenaere and De Fruyt  recommend that the choice of measurement scale for depression 
must include an awareness of the limitations of the commonly used scales; consideration of 
the combined use of self-report and observer rating scales on a study population and the use of 
subscales where indicated.
18
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In literature looking specifically at detecting depression in patients with RA, numerous self-
report and observer rating scales have been used and reported on.
10, 17
 There is general 
consensus that variability exists when using the different scales to detect the presence of 
depression. As such, Covic et al, suggests that some self report scales may require 
modification and possible removal of somatic items; and higher cut–off points for the 
detection of depressive symptoms.
17
 
 
The Arthritis Impact Measurement Scale for depression (AIMS-D) was developed specifically 
to assess mood in arthritis patients.
23
 This six-item subscale is part of the broader AIMS, 
which is used to assess the overall impact of RA. While this subscale has the ability to 
measure the degree of the patient‟s mood, it does not presume to be able to make a clinical 
diagnosis of depression.
16
 
 
Despite advances in the understanding of the difficulties detecting and diagnosing depression; 
and extensive literature on the use of a variety of measurement scales, the task of accurately 
determining the presence of depression within this complex medical disorder, remains a 
difficult one.   
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2.1.4 Treatment of Depression in RA    
 
 The treatment of depression with antidepressant therapy in patients with RA appears to be 
effective. Parker et al in a study looking at the management of depression in RA randomized 
54 subjects to 3 treatment groups: cognitive behavior therapy and antidepressants, attention 
control and antidepressants and antidepressants alone. The subjects were followed up over a 
15-month period and numerous parameters were assessed. The results suggested that there 
was overall improvement in depression in all three groups. There was no difference in the 
overall effectiveness in all three groups, suggesting that antidepressant therapy alone is 
effective. Additionally in this study, there were improvements noted in various other 
parameters including sense of helplessness, self efficiency, coping and psychological 
distress.
24
 
 
 
Ash et al found the antidepressant Dothiepin, to be effective as an analgesic for RA patients 
partly due to its antidepressant action. In addition, beneficial effects were also noted on 
disability and the duration of early morning stiffness in these patients.
25
  
 
This suggests that the benefit of antidepressant therapy may extend beyond the treatment of 
depressive symptomatology alone and include other disease manifestations of RA as well. 
 
Covic et al in looking at a biopsychosocial model of pain and depression in RA, concluded 
that the presence of physical disability, sense of helplessness and passive coping have a 
significant impact on the pain experience and depression in patients with RA. As such, the 
10 
 
authors suggest a biopsychosocial approach to the management of RA, to address not only the 
physical manifestations of the disease, but also the psychological impact. In this way, better 
patient health outcomes can be achieved in this group of patients.
26
 
 
In general, the literature on the holistic management of RA, with specific reference to the 
treatment of depression, supports the use of both antidepressants and psychotherapy; 
interventions which have traditionally been successfully used in non-medical patients 
suffering from depression.    
 
 
2.1.5 The South African Context  
 
The South African RA population presents a unique context in view of its cultural, ethnic and 
socioeconomic diversity. There appears to be a paucity of literature examining the prevalence 
of depression and the psychosocial aspects of this RA patient population.
6
  
 
Venter et al in a study looking at coping styles and depression in South African patients with 
RA and Systemic Lupus Erythematosus (SLE) found that depression was present in 32% of 
RA patients. The predictors of significant depression were found to be stressful life events 
unrelated to illness and the use of a passive, acceptant mode of coping. The authors proposed 
that psychotherapeutic interventions aimed at developing a more active coping strategy may 
be beneficial to improving the mood of these patients and thereby improving their quality of 
life.
6
  
11 
 
In another study, reported to be the first South African study to investigate the association 
between psychosocial, sociodemographic and disease factors; and quality of life in patients 
with RA, Naidoo et al found that psychological factors, especially coping, were more 
significant predictors of self-report of pain and functional status than sociodemographic 
factors. Based on their findings, the authors recommend a holistic and multidisciplinary 
approach to the care of patients with RA.
27
 
 
Mody G, whilst tending to be more medically based still provides valuable insights into the 
profile of RA in Black South Africans.  One such study in a cohort of Black patients in the 
city of Cape Town, found that severe RA disease is not as uncommon in this population group 
as previously believed. The psychological burden of disease can then be expected to be 
significant and worthy of further investigation.
28
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2.2 RA and Pain 
 
Patients with RA typically describe pain as their most disabling symptom. It is unclear 
whether depression is a response to pain in RA; or whether the presence of depression results 
in an exacerbation/elevation of the pain experience. What has clearly emerged from studies is 
that a reciprocal reinforcing relationship exists between pain and depression in RA.
3, 14
 
 
A more recent study examining the impact of pain on RA patients found that depression and   
C - reactive protein (CRP) measurements were significantly associated with pain even after 
adjustments for clinical covariates. In addition it was noted in this study that the risk of severe 
pain increased with depression and CRP measurements in a linear fashion; illustrating the 
close association between these parameters.
29
 Low et al, however, failed to show the same 
finding in 173 women with RA. Instead, this study found no significant association between 
negative mood and CRP and concluded that depressive symptoms in RA may be attributed to 
an overlap between somatic depressive symptoms and RA; and not due to neuroimmune 
modulation.
30
   
 
Abeare et al
 
looked at the relationship between pain, executive functioning and the influence 
of affect and found that increased levels of pain were associated with poor executive 
functioning, once again highlighting the significance of the role of pain in the overall 
functioning of RA patients.
31
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One of the challenges facing clinicians managing patients with RA is the measurement of pain 
which their patients experience. Sokka, in a review of the assessment of pain in patients with 
rheumatoid disease noted that pain is the most prominent symptom in people with arthritis and 
should be routinely evaluated as part of clinical monitoring. The author reviewed both early 
efforts to measure pain tolerance and the later use of patient questionnaires to measure pain; 
and concluded that the most robust quantitative pain measure that can be speedily completed 
and scored is the 10-cm visual analogue scale (VAS).
32
  
 
In view of the findings that pain can be easily measured, albeit subjectively, and that it is 
associated with other important RA and psychosocial outcomes the routine monitoring of pain 
in a clinical setting and the management thereof; should be viewed as an integral aspect of RA 
patient care.
33
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2.3 RA and Functional Disability: 
 
Disability is a defined concept, describing the difficulty in functioning; at the body, person or 
societal levels, in one or more life domains, as experienced by an individual with a health 
condition in interaction with contextual factors.
 34
  
 
 RA patients experience significant disability that affects all domains of their lives. Studies 
looking at the factors associated with disability in RA patients have found that co-morbid 
depression is associated with increased functional disability in these patients.
3, 12, 13
 The 
decline in functional ability in RA patients, particularly with regard to activities of personal 
valued significance, is thought to herald the onset of depression.
35
 Margaretten et al, in a study 
looking at the socioeconomic determinants of disability and depression also concluded that the 
presence of RA functional disability, particularly in a low socioeconomic status population, 
rendered them at high risk of developing depressive symptoms.
36
  
 
The presence of depression, on the other hand, seems to predict a poorer functional outcome 
and greater general disability. Rupp et al
 
studied the association of disability and health-
related quality of life with depressive symptoms, disease activity, pain and radiographic joint 
damage in 307 RA patients over a two-year period.  These authors found that depressive 
symptoms and pain were more important predictors of disability and impaired quality of life 
than disease activity or radiographic damage.
37
  
 
15 
 
In a South African study, examining the functional disability and health-related quality of life 
of Black patients with RA, a strong and positive correlation was found between disease 
activity and physical dysfunction as well as poor overall quality of life. Although this study 
did not specifically look at depression outcomes, it did report that the mental health 
component summary of the Short Form 36 Disability Questionnaire, also correlated strongly 
with functional disability. This once again highlighted the relationship between mental health 
and the outcomes of RA functional disability.
38
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
2.4 RA, Morbidity and Mortality 
 
RA is associated with a number of co morbid medical conditions. The most common of these 
are reported to be depression, hypertension, cardiovascular disease and cerebrovascular 
disease.
4, 39
  
 
Whilst depression has been noted to be an independent risk factor for incident heart disease   
its presence in the context of RA is likely to confer an even greater risk of cardiovascular 
morbidity and even mortality in this patient population.
39, 40
 A study on the Department of 
Veterans Affairs (VA) patients with RA confirmed that depression was a risk factor for 
incident myocardial infarction, with a 40% higher risk of suffering a heart attack in depressed 
patients with RA as compared to their non-depressed counterparts.
39
   
 
The median life expectancy of patients with RA is shortened by 3 to 7 years with a 2.5 fold 
increase in mortality rate.
1
 Amongst other factors associated with increased mortality, an 
association has been found between depression in RA and mortality in a number of  
studies.
41, 42
 In one study looking at this association, co-morbid depression was found to be an 
independent risk factor for mortality in 1290 RA patients who were followed up over an 18-
year period (HR 2.2, 95%CI 1.2-3.9, p = 0.01).
4
 
 
Kvien in a review of the epidemiology and burden of illness in RA, reports that the excess 
mortality seen in RA, has not changed over the past four decades, as may have been seen in 
other chronic disease entities. Whilst the major contributing factors to mortality are 
17 
 
cardiovascular and cerebrovascular disease, unrecognized and untreated depression should be 
considered as the mediating factor that sustains this high mortality rate.
42
  
 
With greater awareness of the impact of depression on mortality in RA, clinicians should now 
actively seek and manage co morbid depression; thereby possibly improving the mortality 
outcome for future sufferers of RA.
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CHAPTER THREE: THE STUDY METHODOLOGY 
 
3.1 Participants: 
 
This study was conducted in the Rheumatology Outpatient clinics at Charlotte Maxeke 
Johannesburg Academic Hospital.  The clinics operate on three days of the week (Monday, 
Wednesday and Friday). Participants were selected from the Wednesday and Friday clinics, 
which comprise patients attending routine follow-up. The Friday clinic consists of primarily 
the treatment- resistant patients. This ensured that the participant sample comprised RA 
patients with varying levels of disease severity.  
 
The sample size was calculated by multiplying the number of study variables by 10 
participants per variable. As such, one hundred participants, of Black, African descent and 
South African nationality, were systematically selected i.e. every third Black patient who 
presented to the clinic on that specific day. This selection process ensured some degree of 
randomization as well as a fair spread of the sample over various clinic days by restricting the 
number of participants selected from each clinic. As patients with a variety of rheumatologic 
conditions are treated at these clinics, only those who fulfilled the 1987 American College of 
Rheumatology criteria for RA were invited to participate in the study.
43
 Potential participants 
had to be 18 years and older. Written, informed consent was obtained from each patient who 
agreed to participate, prior to entering into the study.  
 
19 
 
In this setting, participants speak a variety of Ethnic languages and have varying levels of 
formal education. Only participants who spoke and understood English were selected for the 
study. For those participants who may have encountered some difficulties with this, nursing 
staff, who routinely manage these clinics, were co-opted to assist with translation. As most of 
these patients were regular clinic patients, they were also familiar with the process of routine 
clinical monitoring and the completion of assessment tools used in Rheumatology. As such, 
they were expected to experience little difficulty with the process. 
 
After selection and completion of the informed consent process, participants completed the 
Health Assessment Questionnaire – Disability Index (HAQ-DI), Visual Analogue Scales 
(VAS) for Pain, Fatigue and Disease Activity and Arthritis Impact Measurement Scale 
(AIMS) for depression (AIMS-D) and tension (AIMS-T). The researcher then administered 
the Montgomery-Asberg Rating Scale for Depression (MADRS) and verified all demographic 
data recorded. 
 
Participants were then clinically examined by two experienced rheumatologists and trainee 
rheumatologists, under the supervision of the qualified rheumatologists.  In addition to routine 
clinical monitoring, the following clinical parameters, relevant to this study, were recorded: 
HAQ-DI score, 28- and 36- tender, swollen and deformed joint counts, VAS scores for pain, 
fatigue and disease activity and AIMS score. Participants were then required to provide a 
blood sample for the C-reactive protein (CRP) measurement. The Rheumatologists were blind 
to the MADRS scores at the time of conducting the clinical examination. 
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The researcher assisted with the scoring of the HAQ-DI, AIMS, VAS and Joint Scores. In 
addition, the author was responsible for recording the C-reactive protein values and 
calculating the Disease Activity Score (DAS28) using the available clinical parameters.  
All information relevant to the study was recorded on the data collection form (Appendix B) 
  
3.2 Materials  
 
3.2.1 Sociodemographic Characteristics:  
 
Sociodemograhic data including age, gender, income status and marital status were recorded 
for each participant. Age was recorded in actual years; income status as unemployed, 
employed/pensioner or on a disability pension; and marital status as married or unmarried 
(single/divorced/widowed) 
 
3.2.2 RA Variables: 
 
3.2.2.1 Disease Duration 
This was recorded in number of years. The information was obtained from the patient and 
then verified by the clinical records. It was not always clear as to whether the disease duration 
was calculated from the onset of symptoms or from the date of diagnosis of RA. 
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3.2.2.2 Current Disease Modifying Anti- Rheumatoid Drugs (DMARDS)  
DMARDS are delineated pharmacological agents that appear to have the capacity to alter the 
course of RA and induce true remission in some patients. They constitute the mainstay of 
treatment for RA, in addition to nonsteroidal anti-inflammatory drugs and analgesia, and are 
usually used in combination. A list of the DMARDS that the participant was taking at the time 
of the study was recorded and verified by the most recent prescription chart.   
 
3.2.2.3 Glucocorticosteroid Use 
Glucocorticosteroids are used in RA to suppress aspects of the inflammatory process and 
immunological responses that are characteristic of this disease. In doing so, they provide 
symptomatic relief for the patient. They are very rarely prescribed for chronic use due to their 
long term adverse effects. In view of the documented psychiatric adverse effects of 
glucocorticosteroids, one of which is depression, their use in the study sample population was 
also recorded.
44
 
 
3.2.2.4 Medical History  
RA is commonly associated with other chronic medical conditions. In such patients, the 
burden of disease is expected to be higher, with an anticipated greater vulnerability to 
depression. For this reason, the co morbid medical conditions of the study sample were 
documented. 
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3.2.2.5 Stanford Health Assessment Questionnaire – Disability Index (HAQ-DI) 
The full Stanford Health Assessment Questionnaire was introduced in the 1980s. It was 
developed specifically for patients with RA, to evaluate a number of outcome parameters 
including disability, economic costs, pain, adverse effects of medication and death.
45
 
 
For the purposes of this study, the HAQ-DI (Appendix C) was used to evaluate the degree of 
disability participants experienced at the time of the study. This component of the HAQ 
consists of questions on the patient‟s ability to perform twenty activities. These activities are 
grouped into eight categories and the responses are graded as follows: score 0 – without any 
difficulty, score 1 – with some difficulty, score 2 – with much difficulty and score 3 – unable 
to do. 
 
If the patient uses aides or devices or requires the assistance of another person to perform an 
activity, the score for each category is adjusted accordingly. The total HAQ-DI score is the 
mean of the scores of the eight categories. The score ranges from 0-3. In this study, patients 
with a HAQ-DI = 0 were considered not disabled and those with a HAQ-DI ≥ 1.5 were 
considered severely disabled. These cutoff values are in line with those used in a study on a 
similar study sample and in part, in a similar setting.
7
 As reported in this study, the cutoff of a 
HAQ-DI ≥ 1,5 as a marker of severe disability, has been found in other studies to be a strong 
independent predictor of work disability in early RA.  
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3.2.2.6 Visual Analogue Scales – for Pain, Fatigue and Disease Activity (VAS-P, VAS-F, 
VAS-DA) 
The visual analogue scale (VAS) was developed for use in Rheumatology by Huskisson et  
al.
46
 This scale comprises a 10-cm horizontal line, anchored with labels at each end. For this 
study, the patients were instructed to make a mark, along the 10-cm line as to where they rate 
their pain, fatigue or disease activity respectively, over the past week. The specifiers were as 
follows: for pain, mark 0 stated „no pain‟ and mark 10 stated „severe pain‟; for fatigue – 
„fatigue not a problem‟ and „fatigue a major problem‟ respectively and for disease activity – 
„disease is not active‟ and „disease is very active‟ respectively (Appendix D). 
 
The VAS is widely used in both clinical and experimental settings and has been found to be 
valid and reliable.
47
 Both strengths and limitations of this type of scale have also been 
described.
32, 48  
The choice of its use in this study was based on its ease of use in an outpatient, 
time-limited setting and the familiarity with which this study sample has, in completing the 
VAS.  
 
3.2.2.7 C - reactive protein (CRP) 
CRP, together with the erythrocyte sedimentation rate (ESR), is a serum laboratory 
investigation used widely to assess the presence of acute inflammation and thereby infer 
information about the level of disease activity.CRP measurements may be used to monitor the 
response and efficacy of medication and additionally may be used for its prognostic value, as 
persistently elevated levels can point to higher risk of joint destruction.
49
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 Studies report, however, that acute phase reactants like ESR and CRP can be normal in up to 
40% of patients at their first visit and may be stable over the long-term course of RA; and may 
be influenced by individual genetic factors.
50, 51
 As such, their use as an indicator of active 
disease may be limited. Despite these concerns, ESR and CRP measurements remain routinely 
used laboratory indicators of inflammation in the absence of any proposed alternatives. 
 
There is also some conflicting evidence regarding the association between these inflammatory 
biomarkers and the presence of depression in patients with RA with some studies finding that 
CRP is significantly associated with depressive symptoms; and others not.
29, 30
  
 
For the purpose of this study, the recording of the participant‟s CRP level was two-fold: 1) to 
determine whether there is an association between the CRP level and the presence of 
depression and 2) to enable the calculation of the participants‟ Disease Activity Score  
(DAS 28) 
 
Once participants had completed the clinical assessment by the rheumatologist and the 
depression scale by the author, they were instructed to proceed to the laboratory to provide a 
serum sample for the CRP level. The reference range for the CRP measurement, for the 
laboratory used (National Health Laboratory Services – NHLS) was set at 0.0 – 10.0 mg/L 
with a measurement of >10mg/L indicating the presence of inflammation.  
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3.2.2.8 28-Joint Disease Activity Score (DAS28)  
The original Disease Activity score (DAS) was developed to enable rheumatologists to make 
treatment decisions based on the disease activity present in the patient. The DAS28 is a 
modified version of the DAS, using a 28-joint count for both swollen and tender joints. It 
provides a number on a scale from 0 to 10 to indicate the level of disease activity of RA.  A  
DAS28 above 5.1 indicates high disease activity while a score of below 3.2 indicates low 
disease activity.
52
 
 
In this study, the DAS28 using CRP measurement [DAS28 (CRP)], as opposed to the usual 
ESR measurement, was used. The DAS28 (CRP) shows a similar validation profile to the 
DAS28 (ESR) and is reported to be a useful measure of assessment of disease activity.
53
  
 
The researcher utilized a programme available at the DAS website to calculate the DAS28 
score according to a predetermined formula.
54
  
 
3.2.3 Depression Measurements 
 
3.2.3.1 Arthritis Impact Measurement Scale (AIMS) 
The AIMS is described as a multidimensional index that measures the health status of persons 
with arthritis. It was developed to assess all aspects of the RA, including mental and social 
wellbeing; and not just the physical status of the patient. The scale‟s validity and reliability 
has been documented and it is a clinically useful self- administered tool that can be quickly 
completed in an outpatient setting.
23
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The complete AIMS consists of a total of nine groups of items measuring mobility, physical 
activity, dexterity, social role, social activity, activities of daily living, pain, depression 
(mood) and anxiety. For the purpose of this study, only the depression (mood) and anxiety 
item groups were completed by the study participants (Appendix E). These two groups form 
part of the assessment tool used routinely by the Rheumatology clinicians to assess health 
status in their patients; particularly to screen for depression and anxiety symptoms 
respectively. A score of ≥4 indicates significant depression and/or anxiety symptoms and 
often prompts the Rheumatologist to commence appropriate psychotropic medication or to 
refer to appropriate psychiatric services.   
 
3.2.3.2 Montgomery-Asberg Depression Rating Scale (MADRS) 
The MADRS (Appendix F) is a 10-item clinician-rated depression scale developed in 1979, 
from a 65-item comprehensive psychopathology instrument.
22
 Although the MADRS was 
developed with the intention to detect change in depressive symptoms with antidepressant use, 
it has been widely used to measure depression severity.
55, 56, 57
  
 
Although the 17-item Hamilton Rating Scale for Depression is also widely used in clinical 
trials, the MADRS has been shown to be more precise in estimating depression and is 
therefore thought to be superior. It is also noted to be briefer and more uniform.
21, 55, 56, 57, 58 
 
 
The choice of the MADRS for this study was based on its brevity, inclusion of the 
item„Apparent sadness‟ which allows the researcher to make an objective assessment of the 
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participant‟s mood state and the advantage of a clinician driven scale over a self-report 
questionnaire. In addition, the relatively few somatic items contained in the MADRS are 
thought to assist in reducing criterion contamination.
20, 22
 
 
In terms of scoring of the MADRS, literature is variable as to the recommended cut-off score 
that is most likely to indicate the presence or absence of depression. Whilst the researcher was 
unable to locate any studies to date using the MADRS on RA cohorts, two studies did report 
on its use in patients with Parkinson‟s disease.56, 57 Both studies justified the use of the 
MADRS in this medical population, but showed variable cut-off scores that correlate with a 
diagnosis of depression. Silberman suggested a cut-off of 10, above which patients would be 
classified as depressed.
57
 Leentjies concluded that at a cut-off score of 17 or 18, the MADRS 
showed high specificity and positive predictive value, hence making it a good diagnostic 
tool.
56
 The use of high cut-off scores for the MADRS was also implied by the WHO cross-
sectional, longitudinal study of neuropsychiatric conditions in HIV-AIDS patients. This study 
found that the symptomatic patients scored higher on the MADRS as compared to 
asymptomatic patients and controls.
59
 
 
Based on the above reported findings, the author elected to use a cut-off score of ≥20 to 
indicate the presence of significant depressive symptoms (referred to as depression). This 
score does not necessarily equate to a clinical diagnosis of a major depressive disorder.   
  
 The participants who scored within this range were referred to the psychiatric outpatient 
clinic for a full psychiatric evaluation to confirm a diagnosis of a depressive disorder. For 
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those participants who scored ≥ 20, whilst already on antidepressant therapy, referral to 
psychiatric multidisciplinary services and/or antidepressant dosage adjustments were 
recommended by the author. In the event of actively suicidal participants, provision was made 
for them to be immediately referred to emergency consultation-liaison psychiatric services. 
 
3.2.3.3 Psychiatric History 
The patients attending the Rheumatology clinics are routinely screened for depression and 
anxiety using the AIMS. As such, patients found to be depressed are commenced on 
antidepressant therapy by Rheumatologists. In addition, participants may have a psychiatric 
history that predates the diagnosis of RA. For these reasons, the psychiatric history of the 
participants was recorded. 
 
3.2.3.4 Antidepressant Use   
The prescription of antidepressant medication was also recorded in this study. Experienced 
Rheumatologists who manage this clinic seem comfortable prescribing first line 
antidepressant therapy based on the patients‟ response to the AIMS depression and anxiety 
subscales. If a poor response to antidepressant treatment is noted or further psychiatric 
complications arise, the affected RA patients are then referred to specialized psychiatric 
services within the hospital. 
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3.3 Statistical Analysis 
 
Data was analyzed using the SAS version 9.1 statistical program (SAS, Carey, NC, USA). 
Results are expressed as mean and standard deviation or median [range] for scores of non-
normal distribution; or frequencies and percentages for categorical variables. To determine 
associations between the presence of depression (MADRS score ≥ 20); and sociodemographic 
and RA variables, a Wilcoxon-Mann -Witney test was used. Spearman correlation coefficients 
were used to determine the correlation between the presence of depression (using actual 
MADRS scores) and age, HAQ-DI, VAS (Pain, Fatigue and Disease Activity), CRP, DAS-28, 
AIMS-Depression and AIMS-Tension/Anxiety. Significance was assumed at a both-sided 
value of p < 0.05. 
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CHAPTER FOUR:  RESULTS 
 
4.1 Sociodemographic Characteristics 
 
A total of 99 patients participated in the study. One patient was excluded following a 
diagnostic review that did not find clinical criteria to be consistent with RA. Figure 1 
illustrates the sociodemographic profile of the study sample, in which the majority (85%) of 
the sample was female; unmarried (66%) i.e. single, divorced or widowed and employed or on 
old age pension (56.6%). The mean age was 54.9 ± 9.9 years, ranging from 19-78 years. 
 
 FIGURE 1 SOCIODEMOGRAPHIC CHARACTERISTICS 
 
Gender: F – Female, M – Male; Marital Status: UM - Unmarried, M - Married; Income: UE - Unemployed, E - Employed,  
DP - Disability Pension  
 
 
F UM UE M M E DP 
0% 
10% 
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30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
GENDER MARITAL STATUS INCOME 
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4.2 Depression Variables 
 
4.2.1 Prevalence of Depression 
 
Figure 2 illustrates the depression status breakdown. The majority of the sample, 67(64.7%) 
participants were not found to be depressed, however 35 (35.4%) had an association with 
depression. Of this a total of 13 (13.2%) participants were found to be currently depressed 
according to the MADRS (total score ≥20). The remaining 22 (22.2%) participants were not 
found to be depressed on the MADRS, but were currently stable on antidepressant treatment. 
  
FIGURE 2 DEPRESSION CHARACTERISTICS 
 
MARDS: Montgomery-Asberg Depression Rating Scale; AD: Antidepressants 
 
 
 
64.7% 
22.2% 
7.1% 
6.1% 
NO DEPRESSION STABLE ON ANTIDEPRESSANT (AD) 
DEPRESSED ON MADRS, ON AD DEPRESSED ON MADRS,NOT ON AD 
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The prevalence of depression in this study sample was thus calculated at 13.2% (CI 0.06-0.20) 
if only those participants, who were found to be depressed on the MADRS at the time of the 
study, were used to determine the prevalence.  
 
4.2.2 Psychiatric History 
 
In terms of the past psychiatric history (Table 1), 29 (29.3%) participants had a history of 
depression and were currently still on antidepressant treatment; 6 (6.1%) had a previous 
history of depression and were no longer on treatment; and 2 (2.0%) participants had a history 
of previous alcohol abuse. 
 
4.2.3 Psychotropic Medication 
 
With reference to antidepressant use (Table 1), the majority of those currently using 
antidepressants were prescribed Fluoxetine. The only other antidepressant used in this sample 
for the treatment of depression was Citalopram. Amitriptyline was prescribed, at a low dose, 
for two participants for the treatment of neuropathic pain only.  
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Table 1 Psychiatric History and Antidepressant Use 
DEPRESSION VARIABLE N (%) 
 
Psychiatric History (N=37) 
Current Depression. On treatment 
Past Depression. Not on treatment 
Other Psychiatric Disorder 
 
 
 
29 (29.3) 
6   (6.1) 
2   (2.0) 
Antidepressant Use (N=31) 
Fluoxetine 
Citalopram 
Amitriptyline 
 
 
15 (15.2) 
14 (14.1) 
2   (2.0) 
 
 
4.3 RA Variables 
 
Table 2 illustrates the RA clinical variables of the study sample. The mean disease duration 
was 12.5 ± 9.2 years, the mean HAQ-DI score was 0.92 ± 0.75, the median CRP measurement 
was 8.1mg/L (0.5 – 189.2mg/L) and the DAS28 had a mean of 3.24 ± 1.13. The mean values 
of the various visual analogues scales were similar to each other; as were the mean values of 
the two AIMS subscales. No significant results were found for the use of corticosteroids and 
DMARDS in study sample. Only one participant was prescribed corticosteroids. 
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Table 2 Rheumatoid Arthritis (RA) Variables. N=99 
RA VARIABLE Mean ± SD                   Range 
 
Disease Duration (years) 
HAQ – DI (0-3) 
DAS28 
 
 
12.5 ± 9.2                      1- 41 
1.0 ± 0.8                        0 - 3.6 
3.2 ± 1.1                        1.5 - 7.4 
 
CRP (mg/L) median 
 
VAS- P 
VAS-F 
VAS-DA 
 
AIMS-D 
AIMS-T 
8.1                                  0.5 - 189.2 
 
4.8 ± 3.3                         0 - 10 
4.2 ± 3.2              0 - 10 
4.2 ± 2.9                         0 - 10 
 
3.6 ±1.8                           0 - 7.5 
4.1 ± 1.6                          1 - 9.5 
 
 
Table 3 illustrates the frequency distribution of three RA clinical variables; CRP 
measurement, HAQ-DI, and DAS 28. The majority of the sample, 53 (57.61%) participants 
had an elevated CRP measurement of >10 mmol/L. A majority of 80 (80.81%) of the 
participants had a HAQ-DI score of < 1.5, indicating that they were not classified as disabled. 
For the DAS 28 frequency distribution, a majority of 45 (50%) participants had a low disease 
activity score of < 3.2; 38 (42.22%) participants had an intermediate disease activity score of 
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between 3.2 and 5.1 and 7 (7.78%) participants scored in the high disease activity range of 
>5.2. 
 
Table 3 RA Variables – Frequency Distribution 
RA VARIABLE N (%)  
CRP (mmol/L): 
≤ 10 
> 10 
 
39 (42.4) 
 
53 (57.6) 
 
 
HAQ-DI: 
< 1.5 
≥ 1.5 
DAS 28: 
< 3.2 
3.2 – 5.1 
> 5.1 
 
80 (80.8) 
19 (19.2) 
 
 
45 (50.0) 
 
38 (42.2) 
 
7 (7.8) 
 
 
4.4 Association between Depression and Sociodemographic Characteristics 
 
This study did not find any significant association between the presence and absence of 
depression and the age, gender or income of the study sample. 
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4.5 Association between Depression and RA Disease Variables 
 
Table 4 illustrates the significant associations found in this study between the presence of 
depression and RA variables. The only significant associations were noted between the 
presence of depression and the visual analogue scales for fatigue (VAS-F) and disease activity 
(VAS-DA). Association with AIMS-D and VAS-P were noted to approach significance. No 
significant associations were found between depression and the use of corticosteroids or 
DMARDS. 
 
Table 4 Association between Depression and RA Variables 
RA VARIABLE P VALUE 
 
HAQ – DI 
DAS28 
CRP 
VAS-P 
VAS-F 
VAS-DA 
AIMS-D 
AIMS-T 
Disease Duration 
 
0.12 
0.53 
0.32 
0.07 
0.03† 
0.03† 
0.06 
 
0.28 
 
0.74 
† Significance P ≤ 0.05 
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4.6 Association and Correlation between RA variables and Depression (MADRS) Scores   
 
Table 5 illustrates only the significant relationships found between RA disease variables and 
the actual MADRS scores for the study sample.  
 
MADRS scores were initially found to be significantly associated with HAQ-DI (p = 0.002, 
r = 0.30); VAS-DA (p = 0.001, r = 0.32); VAS-F (p < 001, r = 0.43); AIMS-D (p < 0.001,   
r = 0.40) and AIMS-T (p < 0.001, r = 0.35). A moderately strong correlation was also found 
between MARDS scores and these RA variables. Upon adjusting for age and clinical status, 
significant associations remained with MADRS scores and all five above-mentioned RA 
variables. Correlations between MADRS score and the RA variables HAQ-DI, VAS-DA, 
VAS-F and AIMS-T weakened slightly upon adjustment.  
 
Table 5 Association and Correlation (Spearman r) between RA variables and MADRS  
 
 
a
Adjusted for age and clinical status   
 
 MADRS (Unadjusted) MADRS (Adjusted
a
) 
Variable  
HAQ-DI 
VAS-DA 
VAS-F 
AIMS-D 
AIMS-T      
P- value 
0.002 
 
0.001 
 
< 0.001 
 
< 0.001 
 
< 0.001 
Spearman r                
0.30 
 
0.32 
 
0.43 
 
0.40 
 
0.35 
P- value 
0.01 
 
0.02 
 
< 0.001 
 
< 0.001 
 
0.002 
Spearman r 
0.28 
 
0.26 
 
0.40 
 
0.40 
 
0.33 
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CHAPTER FIVE: DISCUSSION  
 
5.1 Sociodemographic Characteristics 
 
5.1.1 Gender 
 
The study finding of a majority of the sample being female is consistent with literature on 
gender difference seen in RA, which is reported to be 2- 4-fold higher in women.
1, 42
 In Black 
South Africans a higher prevalence of RA in females was also found, with a female -to- male 
ratio of 6.9:1.
60
   
 
Kvien also reports that the reason for this gender difference has not been fully established, but 
that studies have postulated that lower levels of testosterone, high prolactin levels during 
breastfeeding and greater severity of symptoms, may be possible explanations.
42
 
 
5.1.2 Marital Status  
   
The majority of the sample was noted to be unmarried. The category “unmarried” 
encompassed study participants that were single, divorced or widowed. This finding may be 
partially explained by the wide range in the age distribution (19 -78 years) reflecting young 
adults who are yet to be married; and the older-age adults who have already lost their spouses. 
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The contribution of the individual components of this category was not further analyzed, 
hence it is not possible to infer any further information about the contribution of each 
component to this finding. 
  
5.1.3 Income Status 
 
The finding that the majority of the sample was employed is somewhat unexpected in the 
context of a condition like RA. Previous studies have illustrated the negative impact of RA on 
allowing sufferers to sustain employment, particularly in view of the functional disability 
associated with the disease.
1, 62
 
 
The high employment rate may, however, not truly reflect the status quo, as this category 
encompassed both participants in formal employment, informal part-time employment and 
those receiving old age state pensions.  
 
The proportion of each of these groups was not specified in this study. Despite this, those 
formally employed whilst suffering from a chronic, potentially disabling condition, may 
reflect the resilience of the study population, the adequate RA disease control and/or the 
economic demands of a historically disadvantaged population group in a developing country 
that forces them to continue employment, even in the face of the challenges of living with RA.  
 
 
 
40 
 
5.2 Depression Variables 
 
5.2.1 Prevalence of Depression  
  
In this study, 13.2% (CI 0.06 - 0.20) participants were found to be currently depressed. This 
prevalence rate, whilst lower than those found in other studies is in keeping with the studies of 
Pincus et al and Katz which reflect prevalence rates of about 15% after attempting to control 
for criterion contamination.
8,9,10,11,12,13
 
 
The lower prevalence of depression in this study sample can be partially explained by the 
attempt to also control for criterion contamination by the selection of a depression screening 
tool (MADRS) that does not emphasize physical symptoms, that includes an objective item to 
assess depression and by using a high cut-off score to reflect the presence of depression. 
 
In addition, the depression prevalence rate may also be explained by a study sample which 
shows adequate RA disease management (Mean HAQ-DI = 1.0 ± 9.2 and DAS28 = 3.2 ± 1.1) 
and that has routine monitoring and management of depression and anxiety via the AIMS-D 
and AIMS-T respectively. 
 
 It should also be noted, however, that although the 22 (22.2%) participants who were stable 
on antidepressant treatment were not included in determining the prevalence of depression, 
their contribution to the overall association between depression and RA in this study remains a 
meaningful one.  
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5.2.2 Psychiatric History  
 
A total of 37.3% of the study sample had a psychiatric history and were either still currently 
on treatment or now stable and no longer taking psychiatric medication. Two participants 
(2.0%) had a previous history of alcohol abuse, but were stable at the time of the study; whilst 
the remaining 35.3% reported a history of depression. The history of depression, whether past 
or present, is relevant not only to the overall prevalence of depression in this sample, but also 
to the chronic nature of the depression within the context of RA, with some patients  requiring 
long term antidepressant prescription. 
 
5.2.3 Psychotropic Medication 
 
The study finding that the depressed patients who were identified by routine Rheumatology 
screening, were prescribed Selective Serotonin Reuptake Inhibitors (SSRIs) i.e. Fluoxetine 
and Citalopram to treat the depression, is expected as these are first- line antidepressant agents 
that are routinely prescribed by medical specialists other than Psychiatrists, in this hospital 
setting. Patients requiring other classes of antidepressant treatment or who do not respond 
adequately to SSRI antidepressants are generally referred for specialized psychiatric 
management.  
 
The specific use of SSRI antidepressant medication in the treatment of depression in RA was 
reported on in a case study and review by Krishnadas et al.
3
 The report concluded that the  
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significant interaction between the serotonergic and inflammatory systems is worthy of further 
study and may explain the benefit and sustained remission of RA with the use of SSRIs. 
 
SSRIs and other serotonergic antidepressants may thus be the most appropriate psychotropic 
agents to use in this patient population. 
 
 
5.3 RA Variables 
 
5.3.1 Disease Duration 
 
The mean disease duration of 12.5 years (range 1 – 41 years) is long and probably reflects the 
wide age distribution of the study sample i.e. 19 – 78 years, as well as the chronic nature of 
RA.  
 
5.3.2 Disability ( HAQ-DI) 
 
The mean HAQ-DI score of 0.92 and the finding that the majority of the sample scored in the 
“not disabled” range [80 (80.8%) participants scored ≤ 1.5] is somewhat unexpected; as the 
study sample comprised participants from the routine and treatment – resistant RA clinics. 
 
This low rate of disability may, in part, be explained by the possible unequal distribution of 
participants recruited from the routine and treatment-resistant clinics. In addition, 
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consideration must be given to the positive outcomes of close routine monitoring and adequate 
disease management that this tertiary level academic RA clinic at CMJA Hospital provides. 
 
It may also be tempting to ascribe this finding of a low rate of disability to a milder form of 
RA disease in Black South African RA patients. Although very early studies thought this to be 
the case, more recent surveys and studies, as reported by Mody and Meyers, have found that  
severe RA disease is present in this population group.
28
 
    
5.3.3 Disease Activity Parameters (CRP and DAS 28) 
 
Although a small majority of the study sample had an elevated CRP level i.e. 53 (57.6%) 
participants, the mean CRP measurement was still low at 8.1mg/L, with a wide range of                              
0.5 - 189.2mg/L. Again, this seems to indicate a lower level of disease activity in this sample.  
 
The mean DAS28 score of 3.2 with half the sample [45 (50.0%) participants] scoring in this 
range supports the general finding of a low disease activity. Although this is a favourable 
outcome in terms of disease management, consideration must still be given to the remaining 
50% of the study sample who still have intermediate and high disease activity. 
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5.3.4 VAS-P, VAS-F and VAS-DA 
 
The findings related to the Visual Analogue Scales for pain, fatigue and disease activity are 
largely consistent among all three parameters, with values of 4.8, 4.2 and 4.2 respectively. 
 
These relatively lower scores, as indicated subjectively by the participants, seem to support 
the more objective findings of a generally well controlled RA sample. 
 
5.3.5 AIMS – D and AIMS-T 
 
Both the AIMS-D and AIMS-T mean scores were less than 5, with the mean AIMS-T score 
being slightly higher at 4.1±1.6. This finding seems to be in keeping with the lower 
prevalence of depression found in this study sample. As such, it may also indicate a 
favourable correlation between the MADRS as a psychiatric screening tool and the AIMS-D, 
as a depression screening tool used specifically for the arthritis population. 
 
5.4 Association between Depression and Sociodemographic Characteristics 
 
The finding of no significant associations between depression and the age, gender, income and 
marital status of the study sample is not unexpected, as literature is variable with regard to 
study findings.
9
 There is, however, some support for a positive association between the 
presence of depression and younger age, female sex, lower income; and lack of a significant 
and supportive relationship.
 65, 66, 67
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The difference in findings may possibly be explained by the fact that most published literature 
on the sociodemographic profile of depressed RA patients, originates from developed 
countries.
9, 64, 65, 66, 67
 The sociodemographic profile of this study sample, on the other hand, is 
characterized by only Black patients who originate from a formally politically and 
economically disadvantaged background in a developing country. As such, the findings of this 
study may be unique to the represented population group.    
 
In addition, the mean age of the sample was older i.e. 54.9 ± 9.9 years. As literature seems to 
support an association between depression and a younger age group, this may explain the lack 
of significant association with age in this study.  
 
Dickens et al, in a study looking at the association of Depression and RA, found depressed RA 
patients to be significantly more likely to belong to a lower social class (p = 0.002).
64
  Whilst 
this study did not categorize patients into social classes per se, it did consider income status. 
Unemployment would have been expected to be associated with depression in this study 
sample, however, this was not the case. A possible explanation may lie in the high 
unemployment rate in South Africa (25.0% - 3rd Quarter, October 2011); hence 
unemployment amongst patients attending a public sector hospital may be the norm rather 
than the exception.
68
 Additionally, it is possible that a change in employment status, as 
opposed to a long standing status quo of unemployment may represent a greater stressor; that 
then renders the RA patient more vulnerable to depression. 
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Literature on the subject of depression in RA and marital status suggests that the quality of the 
relationship as opposed to the status of marriage is a more significant associate and correlate.  
Both Reese and Waltz highlight this aspect of marital status and, in particular, its impact on 
the clinical outcomes of the patient.
33, 67
 
 
The lack of a significant association between depression and marital status in this study may 
further be explained by two reasons. Firstly, the participants were divided into two categories 
only i.e. married and unmarried. Whist the “unmarried” category included only single, 
divorced and widowed individuals, it may have also included those who were in a significant 
and supportive relationship, but not lawfully married. This is not an uncommon practice 
among certain South African cultural groups, where partners may be “culturally and 
religiously married” but not legally so. In doing so, participants who were categorized as 
single may have, in fact, been in a meaningful and supportive relationship. Secondly, this 
study did not explore the quality of the marital relationship and can therefore not infer any 
other information regarding the impact of marital status on depression except for the noted 
findings.  
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5.5 Association between Depression and RA Disease Variables 
 
5.5.1 Depression and Disability (HAQ-DI) 
 
The significant association between MADRS and HAQ-DI scores as well as the positive 
correlation (r = 0.30) between these two measures, even after adjustment, is in keeping with 
most of the literature on disability and RA.
3, 12, 36, 37
 
 
Lowe, Willand and Eich et al, studied the relative contribution of psychiatric co morbidity to 
work disability (as measured by physical disability scales). They found depression to be an 
independent risk factor of work disability and that this finding was particularly relevant to 
patients with severe RA.
69
  
 
In this study, participants had predominantly mild to moderate RA disease. Based on the 
findings of Lowe et al, this may explain the lack of a strong correlation between MADRS 
scores and disability. Nevertheless, the significant association between these two measures is 
a meaningful one and may indicate a greater need for active management of depression as 
well as physical and vocational rehabilitation. 
 
5.5.2 Depression and VAS-Disease Activity (VAS-DA) 
 
Despite the lack of finding a significant association and correlation between depression and 
the DAS 28 scores and CRP measurement, both of which are used as a measure of disease 
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activity, the VAS-DA was found to be both significantly associated with and positively 
correlated with MADRS scores. 
 
This finding should be interpreted with caution as the VAS-DA is a subjective measure of the 
patient‟s impression of their overall disease activity. As such, it may be influenced by other 
factors including co-morbid medical illness, medication adverse-effects, psychosocial 
stressors and the negative cognitions associated with depression. Conversely, visual analogue 
scales are noted to be both sensitive and clinically useful measures of the subjective aspects of 
RA disease outcomes.
46, 47
 In considering this, the study‟s finding of significant association 
between MADRS scores and VAS-DA, is worthy of further exploration. 
 
5.5.3 Depression and VAS- Fatigue (VAS-F)  
 
There is extensive literature documenting and exploring the symptom of fatigue in patients 
with RA and other musculoskeletal disorders.
70, 71, 72, 73, 74, 75, 76
   
 
Stebbings, Herbison, et al investigated the correlates of fatigue amongst RA and OA patients; 
and found fatigue to be common and severe in both disorders. In RA, fatigue was significantly 
associated with depression and anxiety, but not with pain, disease activity or disability.
70
  
 
The findings in this study were similar, with a significant association between MADRS scores 
and VAS-F (p = < 0.001). A positive correlation was also noted between these two parameters 
(r = 0.43), which weakened slightly after adjustment (r = 0.40). 
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Whilst fatigue may also represent one of the neurovegetative or physical symptoms of 
depression, it is also widely accepted as a significant symptom of rheumatic disease that is 
frequently reported by patients.
71
  
 
RA patients differentiate fatigue related to disease from general tiredness in that fatigue seems 
to encompass both a physical and a mental/cognitive component; typically described as a lack 
of motivation, difficulty concentrating and an inability to think clearly.
72
 The prevalence of 
clinically relevant fatigue is reported to be between 40 and 80%.
70, 73
 Fatigue has also been 
reported to be a common reason for discontinuing work.
74
 
 
Although, fatigue may well be difficult to conceptualize particularly as it is subjective, and 
may represent either an independent symptom of RA disease or a part of other disease 
outcomes, its significant association with depression warrants further consideration. RA 
patients with a past history of depression and suffering from a current “dysphoric” mood were 
found to experience higher levels of fatigue. In addition, the most robust predictor of fatigue 
was found to be, amongst other parameters, a greater number of depressive symptoms  
(r = 0.51; p < 0,0001).
75
 
 
Hence the findings of this study are in keeping with international published literature on 
fatigue and depression in RA. This warrants further investigation of this symptom in this 
cohort of RA patients, particularly in view of the negative impact of fatigue on the patient; and 
the reported benefit of cognitive behavioural therapy and psychosocial interventions in 
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managing fatigue; not withstanding the positive impact of the active management of 
depression.
76
  
 
5.5.4 MADRS, AIMS-D and AIMS-T Scores  
 
The significant association and positive correlation between MADRS scores and both  
AIMS-D and AIMS-T respectively provides useful information regarding the use of these 
AIMS subscales as a good psychological screening tool for depression and anxiety. Whilst the 
AIM-D and AIMS-T do not presume to indicate a diagnosis of a depressive or anxiety 
disorder, their use in the RA population is invaluable in alerting and sensitizing the 
Rheumatologist to the possibility of co-existing psychiatric pathology. 
 
This finding is also important for aligning the MADRS, a depression screening tool used 
predominantly on a psychiatric and general population, with the AIMS, a screening tool 
developed for and used specifically on an arthritis population. Further research into the 
correlation between these screening instruments and their findings on different patient cohorts 
may assist us in developing a better understanding of the depression characteristics within and 
between depression and arthritis patient populations. 
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CHAPTER SIX: CONCLUSIONS AND RECOMMENDATIONS 
 
Depression within the context of a chronic, potentially, disabling condition like RA is a 
significant, but complex phenomenon to understand and investigate. 
 
Extensive published literature exploring these two disease entities, while providing both 
contradictory and compelling evidence of the interaction between them, illustrates that this 
area of research is worthy of our understanding and study, in order to achieve the most 
favourable outcomes in RA. 
 
The prevalence of depression in RA, despite concerns about criterion- contamination, 
suitability of measurement instruments and confounding psychosocial and RA disease factors, 
still remains higher than the general population. In addition to this, the negative health impact 
of depression in RA patients is significant and cannot be ignored if favourable health 
outcomes are to be achieved. 
 
As such, an important goal of comprehensive RA disease management should be to sensitize 
the clinician to the need and the means to detect depression in RA patients. Whilst the AIMS 
subscales for depression (AIMS-D) and tension (AIMS-T) are valuable and validated 
screening tools, there appears to be a need to develop more comprehensive measurement tools 
that may assist in diagnosing psychiatric disorders, like depression, in the unique medical 
population. 
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Despite some of the challenges faced with screening for, detecting and diagnosing depression; 
when identified, depression has been found to be responsive to antidepressant medication. 
However, for those patients who are not responsive or partially responsive to antidepressants, 
the role of psychological interventions like cognitive behavioural therapy and psychosocial 
support need to be considered. In order to facilitate this, a multidisciplinary team approach to 
the management of RA patients with depression, should be employed.
26, 77
    
 
Whilst South African literature regarding depression in RA patients is minimal, there is 
sufficient evidence to indicate that the prevalence and correlates of depression in RA, is in 
keeping with research findings from other developed and developing countries. The 
challenges facing the management of these complex disorders within South Africa are unique 
though, especially in the face of the country‟s political history. The active pursuit of more 
extensive research into this area will assist in developing a better understanding of depression 
within the South African RA population.   
 
Without the active detection and management of depression in RA patients, the health 
outcomes are expected to be characterized by patients who experience higher levels of pain 
and fatigue, a greater degree of physical disability and higher rates of both medical co-
morbidity and mortality. The net result of which again points to poorer health outcomes and 
resultant personal and economic strain.
78
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In this study, the sociodemographic characteristics of the study sample revealed a 
predominantly female, unmarried and employed profile. The gender distribution was not 
unexpected in terms of the predominance of female RA sufferers in general. 
 
The unexpected high level of employment amongst these sufferers of a potentially debilitating 
illness may be unique to the South African developing economic climate and the limited 
availability of state financial assistance; which results in RA sufferers being forced to continue 
employment. 
 
A higher prevalence of depression as compared to the general worldwide population was also 
found in this study cohort; in keeping with published literature on the subject. In addition, 
more than one third of the study cohort reported a current or past psychiatric history, mostly 
related to depression. This represents a significant burden of co morbid disease and may also 
attest to the chronic nature of depression. 
 
The RA variables of this study sample, despite a long duration of RA disease, revealed that 
the majority of participants were not clinically disabled. This was an unexpected finding and 
may be explained by chance, unequal distribution of participant RA disease severity during 
selection and/or good overall disease management and control. 
 
In addition, other RA disease parameters suggested a RA disease cohort with generally low 
disease activity and relatively low visual analogue scale (VAS) scores for pain, fatigue and 
disease activity. This once again indicates a cohort with a lower level of RA disease burden. 
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In the analysis of association and correlation, no significant associations were found between 
depression and the sociodemographic factors studied. However, significant associations and 
positive correlation were found between depression scores (not depressive disorder) and 
disability (HAQ-DI), subjective assessment of disease activity (VAS-DA) and subjective 
assessment of fatigue (VAS-F). Not only are these findings in keeping with some published 
literature, but they are also useful in assisting with the identification RA disease parameters 
that are associated with co morbid depression. In so doing, these parameters may then be 
actively targeted and managed, so as to achieve more effective management of co morbid 
depression and consequent improved RA disease and patient health outcomes. Conversely, the 
associations of these RA parameters with depression may further sensitize the rheumatologist 
to actively seek depression in RA patients presenting with persistently elevated disability, 
subjective disease activity and fatigue scores.  
 
The significant association and positive correlation between RA psychological screening tools 
(AIMS-D and AIMS-T) and those used traditionally in Psychiatry (MADRS) may assist in 
developing a unique measurement tool that can be used to not only screen, but preferably help 
diagnose depressive disorders in this patient population. 
 
The finding of 7.1% of the study cohort being depressed on MADRS despite being currently 
on antidepressant treatment (Figure 2) is an area of concern. This may indicate a need for 
closer monitoring of depression, more regular referral to specialist psychiatric services of 
patients who are not optimally responsive to first-line antidepressant treatment and/ or the 
need for a multidisciplinary approach to the management of depression in these patients. 
55 
 
This would ultimately include the additional input of psychologists, occupational therapists 
and social workers to address the comprehensive needs of these patients who have a high 
burden of disease. 
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CHAPTER SEVEN: LIMITATIONS  
  
Whilst being the first known study to look at depressive symptoms, using a psychiatric 
screening tool in this cohort of Black South Africans with RA, attending this specific public 
health institution, the study nevertheless has a number of limitations. 
 
The study cohort was confined to a specific sector of the South African population i.e. Black 
South Africans attending a tertiary, academic, public health institution. The findings may 
therefore, not be generalisable to the greater South African population where access and 
standard of healthcare may be dependant on resources and settings (provincial variations, 
public versus private healthcare and rural versus urban). In addition, sociodemographic and 
socioeconomic variations between different racial population groups that exist in South 
Africa, may translate into unique RA disease parameters and depression profiles. 
 
Whilst an attempt was made to include a study population that encompassed RA patients with 
variable disease severity, no attempt was made to ensure that the contribution of the 
“treatment-resistant” clinic equaled that of the routine clinic. As such, the lower prevalence of 
depression seen in this study may have arisen from an unequal distribution of RA disease 
severity. 
 
A control group was not used to provide a comparison of the sociodemographic characteristics 
and the depressive symptom prevalence of the study cohort with other Black South Africans. 
Instead, the sociodemographic, RA disease and depression characteristics were simply 
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compared to those described in international, published literature from other developed and 
developing countries. 
 
Although attempts were made to ensure that all RA disease measurement outcomes were 
completed for each participant, there were missing data across all variables, but most notably 
in the CRP measurement, where the patient was expected to proceed to the laboratory to 
provide a blood sample. Ensuring that this sample was taken may have reduced the number of 
lost data and possibly influenced the final data analysis.  
 
The use of a depression screening tool (MADRS) as opposed to a depression diagnostic tool, 
whilst providing useful information regarding depression symptom prevalence, did not equate 
to a diagnosis of a depressive disorder, differentiation of various depressive disorders or 
individual depression characteristics. As such, the comprehensive profile and description of 
depressive disorders in these RA patients was not addressed in this study. 
 
In addition, the high cut-off score of ≥ 20 as a measure of significant depressive symptoms 
may have failed to detect participants experiencing mild to moderate, yet still significant 
depressive symptoms. This, in turn, may be reflected in the low prevalence rate of depression 
found in this study. 
 
What this study does provide is the beginning of a descriptive pathway into the interaction 
between the psychiatric entity of depression and the chronic, potentially disabling condition of 
RA, in a largely understudied population group. In addition, it provides useful findings that 
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may be of influence in the diagnosis and management of depression in chronic medical 
conditions like RA, and in so doing, improve health and health-related economic outcomes in 
South Africa. Lastly, but not least of all, this study may provide a gateway to further research 
into the complex interaction between the human immune system and the human psyche.
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